First National Bank Sioux Falls Decreases Stock Position in Johnson & Johnson $JNJ

First National Bank Sioux Falls reduced its position in Johnson & Johnson (NYSE:JNJ) by 9.8% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,383 shares of the company’s stock after selling 477 shares during the quarter. First National Bank Sioux Falls’ holdings in Johnson & Johnson were worth $670,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of the company. Kera Capital Partners Inc. increased its position in Johnson & Johnson by 33.8% in the second quarter. Kera Capital Partners Inc. now owns 4,116 shares of the company’s stock worth $629,000 after buying an additional 1,039 shares during the last quarter. Private Client Services LLC increased its position in Johnson & Johnson by 11.2% in the second quarter. Private Client Services LLC now owns 1,816 shares of the company’s stock worth $277,000 after buying an additional 183 shares during the last quarter. AdviceOne Advisory Services LLC purchased a new stake in Johnson & Johnson in the first quarter worth $224,000. AG2R LA Mondiale Gestion D Actifs purchased a new stake in Johnson & Johnson in the first quarter worth $18,789,000. Finally, Real Talk Capital LLC purchased a new stake in Johnson & Johnson in the first quarter worth $223,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $178.10 on Friday. The firm has a market capitalization of $428.93 billion, a price-to-earnings ratio of 19.05, a P/E/G ratio of 2.27 and a beta of 0.40. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $181.16. The stock has a fifty day moving average of $170.81 and a 200 day moving average of $161.30. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm’s quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter last year, the company earned $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were paid a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.9%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 55.61%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.16% of the stock is currently owned by company insiders.

Analyst Ratings Changes

JNJ has been the subject of a number of recent research reports. Morgan Stanley raised their target price on Johnson & Johnson from $171.00 to $176.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 17th. Erste Group Bank upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Wednesday, July 23rd. Barclays lifted their price target on Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a research report on Thursday, July 17th. Piper Sandler reiterated an “overweight” rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Finally, Royal Bank Of Canada lifted their price target on Johnson & Johnson from $181.00 to $185.00 and gave the company an “outperform” rating in a research report on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus target price of $176.29.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.